Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa
- 1 February 1985
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 78 (2) , 251-261
- https://doi.org/10.1016/0002-9343(85)90435-8
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Immunology of the monobactam aztreonamAntimicrobial Agents and Chemotherapy, 1984
- Pharmacology of aztreonam after intravenous infusionAntimicrobial Agents and Chemotherapy, 1983
- Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjectsAntimicrobial Agents and Chemotherapy, 1982
- The In Vitro Activity, Human Pharmacology, and Clinical Effectiveness of New beta-Lactam AntibioticsAnnual Review of Pharmacology and Toxicology, 1982
- Monocyclic β-lactam antibiotics produced by bacteriaNature, 1981
- Adverse Effects of Nosocomial InfectionThe Journal of Infectious Diseases, 1979
- A Randomized Comparative Trial of Three Aminoglycosides—Comparison of Continuous Infusions of Gentamicin, Aaikacin and Sisomicin Combined with Carbenicillin in the Treatment of Infections in Neutropenic Patients with MalignanciesMedicine, 1979
- Emergence of Antibiotic Resistance In Hospitals, 1935-1975Clinical Infectious Diseases, 1979
- The Nephrotoxicity of Antimicrobial AgentsNew England Journal of Medicine, 1977
- Antibacterial Activity in Serum and Urine as a Therapeutic Guide in Bacterial InfectionsThe Journal of Infectious Diseases, 1974